4-methoxy-N-(2-methyl-4-nitrophenyl)benzenesulfonamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-methoxy-N-(2-methyl-4-nitrophenyl)benzenesulfonamide
• 化学式: C₁₄H₁₄N₂O₅S
• mdl: MFCD00682806
• 分子量: 322.342
• InChiKey: GLSXKHHECBQBQX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  22
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  110
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-methoxy-N-(2-methyl-4-nitrophenyl)benzenesulfonamide 在 铁粉 、 氯化铵 作用下， 以 甲醇 、 水 为溶剂， 反应 2.0h， 生成 N-(4-amino-2-methylphenyl)-4-methoxybenzenesulfonamide
  参考文献：
  名称：

  Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity

  摘要：

  A class of sulfonamide-substituted diphenylpyrimidines (Sul-DPPYs) were synthesized to improve activity against the focal adhesion kinase (FAK). Most of these new Sul-DPPYs displayed moderate activity against the FAK enzyme with IC50 values of less than 100 nM; regardless, they could effectively inhibit several classes of refractory cancer cell lines with IC50 values of less than 10 mu M, including the pancreatic cancer cell lines (AsPC-1, Panc-1 and BxPC-3), the NSCLC-resistant H1975 cell line, and the B lymphocyte cell line (Ramos cells). Results of flow cytometry indicated that inhibitor 7e promoted apoptosis of pancreatic cancer cells in a dose-dependent manner. In addition, it almost completely induced the apoptosis at a concentration of 10 mu M. Compound 7e may be selected as a potent FAK inhibitor for the treatment of pancreatic cancer. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.05.044
• 作为产物：
  描述：

  对甲氧基苯磺酰氯 、 4-硝基-2-甲苯胺 在 碳酸氢钠 作用下， 以 乙腈 为溶剂， 反应 0.5h， 生成 4-methoxy-N-(2-methyl-4-nitrophenyl)benzenesulfonamide
  参考文献：
  名称：

  Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity

  摘要：

  A class of sulfonamide-substituted diphenylpyrimidines (Sul-DPPYs) were synthesized to improve activity against the focal adhesion kinase (FAK). Most of these new Sul-DPPYs displayed moderate activity against the FAK enzyme with IC50 values of less than 100 nM; regardless, they could effectively inhibit several classes of refractory cancer cell lines with IC50 values of less than 10 mu M, including the pancreatic cancer cell lines (AsPC-1, Panc-1 and BxPC-3), the NSCLC-resistant H1975 cell line, and the B lymphocyte cell line (Ramos cells). Results of flow cytometry indicated that inhibitor 7e promoted apoptosis of pancreatic cancer cells in a dose-dependent manner. In addition, it almost completely induced the apoptosis at a concentration of 10 mu M. Compound 7e may be selected as a potent FAK inhibitor for the treatment of pancreatic cancer. (C) 2017 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2017.05.044

文献信息

• Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity
  作者：Menghua Qu、Zhihao Liu、Dan Zhao、Changyuan Wang、Jianbin Zhang、Zeyao Tang、Kexin Liu、Xiaohong Shu、Hong Yuan、Xiaodong Ma

  DOI：10.1016/j.bmc.2017.05.044

  日期：2017.8

  A class of sulfonamide-substituted diphenylpyrimidines (Sul-DPPYs) were synthesized to improve activity against the focal adhesion kinase (FAK). Most of these new Sul-DPPYs displayed moderate activity against the FAK enzyme with IC50 values of less than 100 nM; regardless, they could effectively inhibit several classes of refractory cancer cell lines with IC50 values of less than 10 mu M, including the pancreatic cancer cell lines (AsPC-1, Panc-1 and BxPC-3), the NSCLC-resistant H1975 cell line, and the B lymphocyte cell line (Ramos cells). Results of flow cytometry indicated that inhibitor 7e promoted apoptosis of pancreatic cancer cells in a dose-dependent manner. In addition, it almost completely induced the apoptosis at a concentration of 10 mu M. Compound 7e may be selected as a potent FAK inhibitor for the treatment of pancreatic cancer. (C) 2017 Elsevier Ltd. All rights reserved.